Document Type

Journal Article

Publication Title

Alzheimer's Research & Therapy

Volume

13

Issue

1

PubMed ID

33863377

Publisher

Springer Nature

School

School of Medical and Health Sciences

RAS ID

35847

Funders

National Health and Medical Research Council / Commonwealth Scientific and Industrial Research Organisation

Comments

Doecke, J. D., Francois, C., Fowler, C. J., Stoops, E., Bourgeat, P., Rainey-Smith, S. R., ... Vanderstichele, H. M. (2021). Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. Alzheimer's Research & Therapy, 13(1), article 79. https://doi.org/10.1186/s13195-021-00812-9

Abstract

Background: CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration. Methods: Biomarkers for β-amyloidopathy (Aβ1–42, Aβ1–40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer’s disease, N = 6). Results: High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability. Conclusions: Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.

DOI

10.1186/s13195-021-00812-9

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS